The source for far-reaching market shifts & what they mean

Will MDMA-assisted therapy be the vanguard for psychedelic-based treatments?

Summary

• With the coming conclusion of the MAPP1/MAPP2 Phase 3 clinical trials, MDMA could become widely available as part of an FDA-approved, therapist-supervised prescription treatment for PTSD (post-traumatic stress disorder) as soon as 2023.
• Psychedelic drugs are demonstrating therapeutic potential for treating an array of mental conditions such as PTSD, treatment-resistant depression, addiction (e.g. opioids, heroin, cocaine, smoking, alcohol), anorexia, and anxiety.
• Society and policymakers are signaling a greater willingness to decriminalize psychedelics for medical uses. Regulators, in turn, are indicating greater openness to therapies that represent a step-up in efficacy over available alternatives.
• Some are already concerned that psychedelics are becoming the next “cannabis bubble.” While psychedelics are showing promise, most of the industry players are still at a relatively early stage — suggesting they may be overvalued in this frothy market.
• The stage is set for a new, innovative class of prescription treatments that can address persistent mental conditions. The winners among the psychedelic pharma companies will have a foothold in an emerging $100B market.

Subscribe to read the full-length brief on the 6Pages website.

6Pages is a market-intelligence service that helps professional decision-makers make better and faster decisions in response to far-reaching shifts in business & tech. We scan thousands of news pieces, identify and connect signals of change, and turn them into deeply researched briefs each week on what’s happening and what it means.

Sign up to get free summaries of our briefs about market shifts and what they mean. You can also follow us on Twitter or LinkedIn for our curated feed of signals.

Share your thoughts with us at hello@6Pages.com.